Knowledge transfer (KT) is the bridge between evidence-based research and the use of that research by those responsible for health care policy and decision making.
The World Health Organization describes knowledge transfer as a mechanism to close the ”know-do” gap – the gap between what is known and what is done. “The processes from knowledge generation to action are complex, and influenced by factors including stakeholder involvement, local context, perceived relevance, and the knowledge itself. Knowledge needs to be contextualized to be meaningful.”
Effective knowledge transfer entails an ongoing exchange between research producers and research users, often by means of traditional communications activities.
While the Canadian Agency for Drugs and Technologies in Health has always engaged in knowledge transfer, we have now stepped up our efforts by employing a broader team approach that draws on management, researchers, knowledge transfer officers, liaison officers, and communications staff.
Our knowledge transfer activity, which initially focused on Health Technology Assessment (HTA) reports, is expanding to include research produced by the Canadian Optimal Medication Prescribing and Utilization Service (COMPUS) and the Common Drug Review (CDR).